Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker NSP
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 29, 2026 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 29, 2026 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 20, 2026 | NSP Insperity, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 20, 2026 | NSP Insperity, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 30, 2026 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 10, 2026 | NSP Insperity, Inc. | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Feb 10, 2026 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 16, 2025 | NSP Insperity, Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Dec 16, 2025 | NSP Insperity, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 3, 2025 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 3, 2025 | NSP Insperity, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 1, 2025 | NSP Insperity, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 1, 2025 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 1, 2025 | NSP Insperity, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 27, 2025 | NSP Insperity, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 27, 2025 | NSP Insperity, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 29, 2025 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 10, 2025 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 21, 2024 | NSP Insperity, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 31, 2024 | NSP Insperity, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
20 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances